10.6084/M9.FIGSHARE.17143004
Yu Bai
Yu
Bai
Xu Ma
Xu
Ma
Yan-hua Zhang
Yan-hua
Zhang
Systematic review and meta-analysis of the predictive power of <i>MTHFR</i> polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients
<p>We conducted a meta-analysis to determine if <i>MTHFR</i> polymorphisms are effective biomarkers for non-small cell lung cancer (NSCLC) patient survival and pemetrexed (PEM) treatment toxicity. Because of data heterogeneity, fixed or random effects models were chosen, and pooled HRs and 95% confidence intervals (CIs) were calculated. No correlation between <i>MTHFR</i> 677 C > T polymorphism and progression-free survival (PFS) or overall survival (OS) was detected in NSCLC patients; however, patients with the T allele benefited more than those with the wild-type allele. Two papers reported hematologic toxicity of single-agent PEM treatment in patients with the <i>MTHFR</i> 677 C > T polymorphism. However, data on <i>MTHFR</i> polymorphisms and toxicity could not be combined, even though publication bias and sensitivity analysis results were stable and reliable. We conclude that the <i>MTHFR</i> 677 C > T polymorphism could not predict PEM efficacy in NSCLC patients; however, the T allele may increase the risk of haematological toxicity. A large-scale clinical trial is recommended.</p>
Medicine
Genetics
Pharmacology
Biological Sciences not elsewhere classified
Cancer
Taylor & Francis
2021
2021-12-08
2023-06-06
Journal contribution
32937 Bytes
10.1080/1120009X.2021.2009989
CC BY 4.0